文献速递其他结缔组织病

JAK-1抑制可抑制人唾液腺中干扰素诱导的BAFF产生:原发性干燥综合征的潜在治疗策略

JAK-1 Inhibition Suppresses Interferon-Induced BAFF Production in Human Salivary Gland: Potential Therapeutic Strategy for Primary Sjögren's Syndrome.
PubMed 文献 · Arthritis Rheumatol · 2018-10-24

研究分析原发性干燥综合征患者外周血单核细胞与唾液腺组织的差异表达基因,发现IFNG和BAFF在患者唾液腺中表达增高且IFIT2与BAFF表达显著相关。JAK抑制剂非戈替尼可抑制人原代唾液腺上皮细胞中干扰素诱导的差异表达基因及BAFF转录,并在NOD/ShiLtJ小鼠中增加唾液流率、减少唾液腺淋巴细胞浸润。结论认为JAK抑制可控制唾液腺上皮细胞异常活化,可能成为原发性干燥综合征的新治疗策略。

要点

  • 原发性干燥综合征患者唾液腺中IFNG和BAFF表达增高,IFIT2与BAFF表达显著相关。
  • JAK抑制剂非戈替尼抑制人原代唾液腺上皮细胞中干扰素诱导的差异表达基因与BAFF转录。
  • 非戈替尼处理的NOD/ShiLtJ小鼠唾液流率增加、唾液腺淋巴细胞浸润明显减少。

核心结论

  • JAK抑制可控制唾液腺上皮细胞的异常活化,可能成为原发性干燥综合征的新治疗策略。

研究设计与样本

  • 分析原发性干燥综合征患者外周血单核细胞及血液与唾液腺组织的公共差异表达基因数据集,并按焦点评分验证唾液腺中的表达。
  • 在人原代唾液腺上皮细胞中用逆转录聚合酶链反应分析非戈替尼对差异表达基因及BAFF信使RNA表达的抑制。
  • 用人唾液腺类器官培养结合小干扰RNA敲低或JAK抑制剂处理,判定差异表达基因与BAFF的关联及BAFF调控。
  • 对8周龄NOD/ShiLtJ小鼠每周3次腹腔注射非戈替尼1.5 mg/kg以分析疾病表现。
  • 在人和小鼠唾液腺上皮细胞中评估STAT信号。

主要发现

  • 按焦点评分评估,原发性干燥综合征患者唾液腺中差异表达基因IFNG和BAFF表达增高。
  • IFIT2与BAFF表达之间存在显著相关性。
  • JAK抑制剂抑制人原代唾液腺上皮细胞中干扰素诱导的差异表达基因及BAFF转录。
  • 在人唾液腺类器官培养中,敲低差异表达基因或抑制JAK均使BAFF分泌减少。
  • 非戈替尼处理的小鼠唾液流率增加,唾液腺淋巴细胞浸润明显减少。

关键数值与推荐

  • JAK抑制剂调控人唾液腺上皮细胞中IFNα和IFNγ诱导的pSTAT-1Y701、pSTAT-3Y705及活化STAT-3蛋白抑制剂(PIAS-3)。
  • JAK抑制剂调控小鼠唾液腺上皮细胞中IFNγ诱导的pSTAT-1Y701、pSTAT-3S727及PIAS-1。
  • 非戈替尼以1.5 mg/kg腹腔注射、每周3次用于8周龄NOD/ShiLtJ小鼠。

临床怎么用

  • 原文结论认为JAK抑制可能成为原发性干燥综合征的新治疗策略,未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine whether a JAK inhibitor regulates functional responses of human salivary gland epithelial cells (SGECs) and disease parameters in an animal model of Sjögren's syndrome (SS). METHODS: Common differentially expressed genes (DEGs) were analyzed among peripheral blood mononuclear cells from patients with primary SS and other data sets, using blood and SG tissue. Validation of expression in SGs was analyzed by focus score. Inhibition of messenger RNA expression of DEGs and BAFF by filgotinib was analyzed using reverse transcription-polymerase chain reaction in primary SGECs. SG organoid cultures were used to determine the association between DEGs and BAFF via knockdown using small interfering RNAs or to determine regulation of BAFF by JAK inhibitor. Filgotinib (1.5 mg/kg) was intraperitoneally injected into 8-week-old NOD/ShiLtJ mice 3 times per week to analyze manifestations of disease. Finally, STAT signaling was assessed in human and mouse SGECs. RESULTS: Expression of the DEGs IFNG and BAFF increased in SGs from patients with primary SS, as assessed by focus score. There was a significant correlation between IFIT2 and BAFF expression. JAK inhibitor suppressed interferon (IFN)-induced transcription of DEGs and BAFF in human primary SGECs. Knockdown of DEGs or inhibition of JAK caused reduced secretion of BAFF in human SG organoid cultures. In addition, filgotinib-treated mice exhibited increased salivary flow rates and marked reductions in lymphocytic infiltration of SGs. JAK inhibitor regulated IFNα- and IFNγ-induced pSTAT-1Y701 , pSTAT-3Y705 , and protein inhibitor of activated STAT-3 (PIAS-3) in human SGECs as well as IFNγ-induced pSTAT-1Y701 , pSTAT-3S727 , and PIAS-1 in mouse SGECs. CONCLUSION: JAK inhibition controls aberrant activation of SGECs and may be a novel therapeutic approach for primary SS.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Lee J, Lee J, Kwok SK, et al. JAK-1 Inhibition Suppresses Interferon-Induced BAFF Production in Human Salivary Gland: Potential Therapeutic Strategy for Primary Sjögren's Syndrome. Arthritis Rheumatol. 2018. PMID: 29927095. doi:10.1002/art.40589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。